Provectus Biopharm CEO acquires $70K 8% convertible note, Series D-1

Provectus Biopharmaceuticals, Inc. reported a Form 4 transaction by its CEO and director, Edward Pershing, involving an 8% unsecured convertible promissory note tied to the company’s 2025 financing.

Rhea-AI Filing Summary

Provectus Biopharmaceuticals, Inc. reported a Form 4 transaction by its CEO and director, Edward Pershing, involving an 8% unsecured convertible promissory note tied to the company’s 2025 financing. On 11/26/2025, the reporting person acquired a note with principal of $70,000 that is convertible into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.

The filing states that the note’s outstanding principal and interest may be converted into Series D-1 Preferred Stock at any time while it is outstanding, and will automatically convert at the same price per share twelve months after the note’s issue date. Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock, and the preferred shares will automatically convert into common stock on June 26, 2026, unless converted earlier under their terms.

Insider Trade Summary

Grant/Award: 0 shares

Grant/Award 1 txn

Insider Pershing Edward

Role CEO

Type	Security	Shares	Price	Value
Grant/Award	8% Unsecured Convertible Promissory Note	0	$0.00	$0.00

Holdings After Transaction: 8% Unsecured Convertible Promissory Note — 0 contracts (Direct)

Footnotes (2)

1. F1. The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "Note") at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note. The Note was issued pursuant to the Issuer's 2025 Financing.
2. F2. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Preferred Stock will automatically convert into Common Stock on June 26, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Preferred Stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PVCT report in this Form 4?

The company reported that CEO and director Edward Pershing acquired an 8% unsecured convertible promissory note with principal of $70,000 on 11/26/2025, related to Provectus Biopharmaceuticals’ 2025 financing.

What are the conversion terms of the 8% unsecured convertible promissory note at Provectus Biopharmaceuticals (PVCT)?

The filing states that the note’s outstanding principal and interest may be converted at any time into Series D-1 Convertible Preferred Stock at a price of $2.862 per share, and will automatically convert at the same price twelve months after the note’s issue date.

How many shares of Series D-1 Preferred Stock are linked to the reported PVCT note?

Table II shows that the derivative security relates to 24,459 shares of Series D-1 Convertible Preferred Stock as the securities underlying the 8% unsecured convertible promissory note.

How does the Series D-1 Convertible Preferred Stock convert into Provectus Biopharmaceuticals common stock?

According to the explanation, each share of Series D-1 Preferred Stock is convertible into 10 shares of Provectus Biopharmaceuticals’ common stock, par value $0.001 per share.

When will the Series D-1 Preferred Stock at PVCT automatically convert into common stock?

The disclosure states that the Series D-1 Convertible Preferred Stock will automatically convert into common stock on June 26, 2026, unless it is converted into common stock earlier in accordance with its terms.

What is Edward Pershing’s role at Provectus Biopharmaceuticals, Inc. (PVCT)?

The Form 4 identifies Edward Pershing as both a director and an officer of Provectus Biopharmaceuticals, serving in the role of CEO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/28/2025 - 12:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pershing Edward

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TN 37929

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
8% Unsecured Convertible Promissory Note	$2.862	11/26/2025		A		$70,000		11/26/2025	11/26/2026	Series D-1 Convertible Preferred Stock(1)(2)	24,459	$0	$1,345,000	D

Explanation of Responses:

1. The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "Note") at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note. The Note was issued pursuant to the Issuer's 2025 Financing.

2. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Preferred Stock will automatically convert into Common Stock on June 26, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Preferred Stock.

	/s/ Edward Pershing	11/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.